Related Experiment Videos
Update on the European Vasculitis Study Group trials.
1Senior Lecturer in Renal Medicine, Renal Unit, St. Helier Hospital, Carshalton, Surrey, UK. djayne@sghms.ac.uk
Current Opinion in Rheumatology
|January 10, 2001
Summary
Azathioprine is as effective as cyclophosphamide for maintaining remission in generalized vasculitis. European studies harmonize treatment and explore new therapies for ANCA-associated vasculitis.
Area of Science:
- Rheumatology
- Immunology
- Clinical Trials
Background:
- European collaborative studies established antineutrophil cytoplasmic antibodies (ANCA) association with vasculitis.
- ANCA is a key diagnostic tool for vasculitis.
- The European Vasculitis Study Group harmonizes and optimizes vasculitis therapy.
Purpose of the Study:
- To evaluate current and novel therapeutic strategies for vasculitis.
- To harmonize and optimize vasculitis treatment through multicenter randomized controlled trials.
- To identify prognostic markers and monitoring tools for vasculitis.
Main Methods:
- Conducted multicenter randomized controlled trials (e.g., CYCAZAREM).
- Investigated treatments including azathioprine, cyclophosphamide, methotrexate, and plasma exchange.
- Examined strategies for acute disease, remission maintenance, and relapse prevention.
Main Results:
- Azathioprine demonstrated equal efficacy to cyclophosphamide in maintaining remission for generalized vasculitis (CYCAZAREM trial).
- Ongoing trials explore other agents and strategies for acute and long-term management.
- Studies are evaluating prognostic markers and the impact of ANCA and infection on relapse.
Conclusions:
- Azathioprine offers an effective alternative to cyclophosphamide for vasculitis remission maintenance.
- Established European infrastructure facilitates future therapeutic strategy testing.
- Further research is ongoing to optimize vasculitis treatment and patient outcomes.